Up to your usual tricks, Harvett?
Rasul: The majority of patients were previously treated with abiraterone/enzalutamide (69%) and docetaxel/cabazitaxel (67%)
LuPIN: All patients had received and failed two prior lines of therapy (chemotherapy and androgen signalling inhibitors) and most patients (29/32) had failed a third line of therapy (another chemotherapy) prior to entering the trial.
These trials have wildly different patient criteria. You should include a disclaimer with your posts, to acknowledge your unbalanced views.
- Forums
- ASX - By Stock
- NOX
- Ann: Pronounced survival benefit in LuPIN interim trial data
Ann: Pronounced survival benefit in LuPIN interim trial data, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $37.99M |
Open | High | Low | Value | Volume |
12.5¢ | 14.0¢ | 11.0¢ | $509.7K | 4.065M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 243 | 11.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.0¢ | 169846 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 721591 | 0.110 |
12 | 273315 | 0.105 |
11 | 696405 | 0.100 |
1 | 25357 | 0.098 |
3 | 21249 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 169846 | 6 |
0.125 | 305772 | 3 |
0.130 | 335797 | 4 |
0.135 | 591881 | 7 |
0.140 | 176192 | 10 |
Last trade - 13.24pm 03/09/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |